Literature DB >> 26997425

Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study.

Jacoba M Maurer1, Susan Hofman2, Reinout C A Schellekens3, Wouter F Tonnis4, Annelien O T Dubois5, Herman J Woerdenbag6, Wouter L J Hinrichs7, Jos G W Kosterink8, Henderik W Frijlink9.   

Abstract

The monoclonal antibody infliximab is one of the cornerstones in the treatment of Crohn's disease. Local delivery of infliximab would be an alternative to overcome the inherent disadvantages of intravenous therapy. For this purpose 5mg infliximab tablets were developed. To stabilize the antibody during production and storage it was incorporated in a sugar glass containing the oligosaccharide inulin. To obtain colon-specific release a ColoPulse coating was applied. The tablets were stored for 16 months under different conditions based on ICH climatic zone I.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ColoPulse; Colon specific delivery; Crohn’s disease; Formulation; Infliximab; Oral delivery; Protein stability

Mesh：

Substances：

Year:  2016        PMID： 26997425     DOI： 10.1016/j.ijpharm.2016.03.027

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  7 in total

1.  Characterization of Grinding-Induced Subvisible Particles and Free Radicals in a Freeze-Dried Monoclonal Antibody Formulation.

Authors:  Zhen-Yi Jing; Guo-Li Huo; Min-Fei Sun; Bin-Bin Shen; Wei-Jie Fang
Journal:  Pharm Res       Date:  2022-01-26       Impact factor: 4.200

2.  The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production.

Authors:  Gaurav Kanojia; Rimko Ten Have; Arjen Bakker; Koen Wagner; Henderik W Frijlink; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

3.  Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process.

Authors:  Bahez Gareb; Silke Posthumus; Max Beugeling; Pauline Koopmans; Daan J Touw; Gerard Dijkstra; Jos G W Kosterink; Henderik W Frijlink
Journal:  Pharmaceutics       Date:  2019-08-23       Impact factor: 6.321

Review 4.  How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.

Authors:  Piotr Eder; Aleksandra Zielińska; Jacek Karczewski; Agnieszka Dobrowolska; Ryszard Słomski; Eliana B Souto
Journal:  J Nanobiotechnology       Date:  2021-10-29       Impact factor: 10.435

Review 5.  In Vitro Methodologies for Evaluating Colon-Targeted Pharmaceutical Products and Industry Perspectives for Their Applications.

Authors:  Mauricio A García; Felipe Varum; Jozef Al-Gousous; Michael Hofmann; Susanne Page; Peter Langguth
Journal:  Pharmaceutics       Date:  2022-01-26       Impact factor: 6.321

6.  Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.

Authors:  Katie Amssoms; Philip A Born; Max Beugeling; Ben De Clerck; Ellen Van Gulck; Wouter L J Hinrichs; Henderik W Frijlink; Niels Grasmeijer; Guenter Kraus; Roger Sutmuller; Kenny Simmen; Lieven Baert
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

Review 7.  New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.

Authors:  Adrian H Teruel; Isabel Gonzalez-Alvarez; Marival Bermejo; Virginia Merino; Maria Dolores Marcos; Felix Sancenon; Marta Gonzalez-Alvarez; Ramon Martinez-Mañez
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.